ÂÜÀòÂÒÂ×

Chi-Wei Lu has extensive work experience in various roles and industries. In 2022, they joined Teclison as the Director of Program Management. Prior to this, they worked as an Associate Director Clinical Research Scientist at Insmed Incorporated starting from 2020. From 2018 to 2020, they held the position of Director of Clinical Research Science at Sorrento Therapeutics, Inc. Before that, from 2014 to 2018, they served as the Director of Research at the Women's Health Institute at Rutgers Robert Wood Johnson Medical School, and simultaneously worked as a Resident Scientist at the Child Health Institute of New Jersey from 2011 to 2018. Their earliest role was as the Director of the Stem Cell Core Facility at the University of Medicine and Dentistry of New Jersey from 2008 to 2011.

Chi-Wei Lu has an extensive education history in the field of biomedical research and stem cell biology. The chronology of their education is as follows:

From 2013 to 2017, Chi-Wei Lu attended Harvard Medical School, where they pursued postdoctoral studies in stem cell biology and leukemia.

Prior to their time at Harvard, from 2012 to 2013, they completed another postdoctoral research position at the Whitehead Institute for Biomedical Research. During this period, they focused their studies on leukemia, oncology, and cell migration.

In 1996, Chi-Wei Lu obtained a Doctor of Philosophy (Ph.D.) in Biochemistry from Rutgers University. This degree marked a significant milestone in their academic journey, providing him with a strong foundation in the field.

Before pursuing their Ph.D., they obtained a Bachelor's Degree in Clinical Laboratory Science/Medical Technology/Technologist from National Taiwan University. Chi-Wei completed their undergraduate studies from 1990 to 1994.

Additionally, Chi-Wei Lu has also obtained a Certified Clinical Research Professional (CCRP) certification from the Society of Clinical Research Associates (SOCRA), although specific dates and details regarding this certification are not provided.